New drug combo targets hard-to-treat cancers with genetic mutation
NCT ID NCT06496568
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 28 times
Summary
This early-phase study tests a drug called inavolisib, alone or with immunotherapy, in people whose cancers have a specific PIK3CA gene change. About 30 adults with advanced head and neck or other solid tumors will take part. The goal is to see if the treatment is safe and shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PIK3CA-MUTATED CANCERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BC Cancer Vancouver Centre
RECRUITINGVancouver, British Columbia, V5Z 4E6, Canada
-
California Cancer Associates for Research & Excellence, Inc.
WITHDRAWNSan Marcos, California, 92069, United States
-
Jewish General Hospital
RECRUITINGMontreal, Quebec, H3T 1E2, Canada
-
Moores Cancer Center at UC San Diego Health
WITHDRAWNLa Jolla, California, 92093, United States
-
Princess Margaret Cancer Center
RECRUITINGToronto, Ontario, M5G 2M9, Canada
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
-
Seoul National University Hospital
WITHDRAWNSeoul, 03080, South Korea
-
Vanderbilt-Ingram Cancer Ctr
RECRUITINGNashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.